Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions ... (original) (raw)

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic risk factors, and other obesity-related comorbidities1-6 ......read full story